Muhammad Abdul-Ghani (R A DeFronzo, Ralph DeFronzo, Ralph A DeFronzo)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 27

Top Topics

Combination Therapy

Ankylosing Spondylitis

Left Ventricular

Top Venues

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
J David Spence, Catherine Viscoli, Walter N Kernan, Lawrence H Young, Karen Furie, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani, Paresh Dandona, Catherine M Viscoli
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes, obesity & metabolism 24 (6) (2022)
John Armato, Muhammad Abdul-Ghani, Shih-Ting Chiu, Deanna Rider, Ronald Ruby
Are angiotensin-converting enzyme inhibitors/angiotensin receptor blockers associated with reduced severe acute respiratory syndrome coronavirus 2 infections and improved outcomes, and does race matter? Diabetes, obesity & metabolism 24 (12) (2022)
Muhammad Abdul-Ghani, George L Bakris
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes, obesity & metabolism 24 (7) (2022)
Tamam Abdul-Ghani, Curtiss Puckett, Osama Migahid, Siham Abdelgani, Ayman Migahed, John Adams, Curtis Triplitt, Muhammad Abdul-Ghani, Amin Jayyousi, Muhammad A Abdul-Ghani
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies. Diabetes, obesity & metabolism 24 (9) (2022)
Olga Lavynenko, Muhammad A Abdul-Ghani, Mariam Alatrach, Curtiss Puckett, John Adams, Siham Abdelgani, Naim Alkhouri, Curtis Triplitt, Geoffrey D Clarke, Juan A Vasquez, Jinqi Li, Eugenio Cersosimo, Francesco Rubino, Muhammad Abdul-Ghani
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes, obesity & metabolism 24 (5) (2022)
Alexander J Moody, Marjorie Molina-Wilkins, Geoffrey D Clarke, Aurora Merovci, Carolina Solis-Herrera, Eugenio Cersosimo, Robert J Chilton, Patricia Iozzo, Francesco Rubino, Muhammad A Abdul-Ghani, Muhammad Abdul-Ghani
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, obesity & metabolism (2022)
S Abdelgani, C Puckett, J Adams, C Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. The Journal of clinical endocrinology and metabolism 106 (12) (2021)
Siham Abdelgani, Curtiss Puckett, John Adams, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study. Diabetes, obesity & metabolism 23 (7) (2021)
Muhammad A Abdul-Ghani, Osama Migahid, Ayman Megahed, Muhammad Abdul-Ghani, Ebaa Al-Ozairi, Amin Jayyousi
Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study. Diabetes, obesity & metabolism 22 (12) (2020)
Muhammad Abdul-Ghani, Silvio Inzucchi, Muhammad Abdul-Ghani, Steven E Nissen
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes & vascular disease research 16 (2) (2019)
Eleuterio Ferrannini, Simona Baldi, Juan Pablo Frias, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Muhammad Abdul-Ghani
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. Diabetes, obesity & metabolism 22 (1) (2019)
Muhammad Abdul-Ghani, Ralph A De Fronzo
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes care 40 (8) (2018)
Mariam Alatrach, Christina Agyin, John Adams, Robert J Chilton, Curtis Triplitt, Muhammad Abdul-Ghani, Eugenio Cersosimo
Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes. Endocrinology, diabetes & metabolism 1 (4) (2018)
Christopher E Shannon, Aurora Merovci, Juan Xiong, Devjit Tripathy, Felipe Lorenzo, Donald McClain, Muhammad Abdul-Ghani, Luke Norton, Ralph A De Fronzo
Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. Diabetes 67 (12) (2018)
Robert Martinez, Hussein Al-Jobori, Ali M Ali, John Adams, Muhammad Abdul-Ghani, Curtis Triplitt, Ralph A De Fronzo, Eugenio Cersosimo
Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. Diabetes 67 (6) (2018)
Geoffrey D Clarke, Marjorie Molina-Wilkins, Carolina Solis-Herrera, Verna Mendez, Adriana Monroy, Eugenio Cersosimo, Robert J Chilton, Muhammad A Abdul-Ghani, Muhammad Abdul-Ghani
Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. Endocrinology, diabetes & metabolism 1 (2) (2018)
Muhammad A Abdul-Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Mohammad Fawaz, Muhammad Abdul-Ghani, Amin Jayyousi
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. Diabetes, obesity & metabolism 21 (3) (2018)
Muhammad Abdul-Ghani, Eleuterio Ferrannini, Guntram Schernthaner, Stefan Hantel, Ulrich Elsasser, Christopher Lee, Thomas Hach, Søren S Lund
Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Endocrinology, diabetes & metabolism 1 (2) (2018)
Muhammad Abdul-Ghani
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes, obesity & metabolism 19 (10) (2017)
Muhammad Abdul-Ghani, Ralph A De Fronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh, Robert E J Ryder
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes care 40 (7) (2017)
Geoffrey D Clarke, Carolina Solis-Herrera, Marjorie Molina-Wilkins, Sandra Martinez, Aurora Merovci, Eugenio Cersosimo, Robert J Chilton, Patricia Iozzo, Francesco Rubino, Muhammad Abdul-Ghani, Ralph A De Fronzo
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes care 40 (11) (2017)
Hussein Al-Jobori, Giuseppe Daniele, Eugenio Cersosimo, Curtis Triplitt, Rucha Mehta, Luke Norton, Ralph A De Fronzo, Muhammad Abdul-Ghani
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. Diabetes 66 (7) (2017)
Muhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Curtis Triplitt, Ralph A De Fronzo
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose. Diabetes 66 (9) (2017)